APYX Q3 2023: Advanced Energy Generators Drive 70% U.S. Growth, Yet Guidance Cut on Capital Slowdown
APYX delivered 31% revenue growth led by advanced energy generators, but cut full-year guidance as U.S. capital equipment demand weakened and sales execution lagged. Operational improvements and new FDA clearances are fueling international momentum, yet macro headwinds and a CFO transition add complexity to the outlook. Investors should focus on utilization trends and the impact of commercial team changes heading into 2024.
Summary
- Capital Equipment Headwinds: Softer U.S. demand and delayed purchases forced a downward guidance revision.
- Execution Reset: Sales and marketing reorganization aims to recover productivity and drive utilization.
- Utilization Focus: Consumables and new indications remain critical for sustained growth into 2024.
Business Overview
APYX Medical Corporation is a medtech company specializing in advanced energy solutions for cosmetic surgery, primarily through its Renuvion technology, which offers minimally invasive tissue contraction and body contouring. The business operates in two segments: Advanced Energy, which includes generators and handpieces for cosmetic procedures, and OEM, which supplies products to other device manufacturers. APYX generates revenue from both capital equipment sales (generators) and recurring consumable sales (handpieces), with a growing focus on utilization-driven, procedure-based revenue.
Performance Analysis
APYX posted 31% year-over-year revenue growth in Q3, reaching $12 million, powered by a 39% increase in Advanced Energy sales to $9.8 million. The U.S. market saw generator sales surge over 70%, with most growth coming from new customers adopting the next-generation APEX One console. Internationally, generator and handpiece sales both grew strongly, especially in Latin America, reflecting improved distributor traction and regulatory clarity.
However, the quarter fell over $3 million short of internal revenue expectations, primarily due to a weaker U.S. capital equipment environment, pronounced summer seasonality, and underperformance in sales execution. Handpiece sales in the U.S. were flat, and management cited delayed purchases tied to high interest rates and economic uncertainty. Despite these challenges, gross profit margin improved to 66.6% due to favorable segment mix, and operating leverage reduced net loss by 20% year over year. Cash flow improved significantly, aided by an IRS tax refund and a new $45 million credit facility that replaced prior debt on better terms.
- Generator-Driven Momentum: New customer adoption of APEX One consoles was the primary driver of U.S. growth.
- International Acceleration: Latin America led international gains, with handpiece sales up over 40%.
- Operating Leverage: Cost control and mix shift improved margins despite revenue miss.
Overall, APYX’s recurring consumable revenue now represents more than half of trailing 12-month Advanced Energy sales, underscoring the importance of utilization for future growth.
Executive Commentary
"While we are ultimately disappointed with the softer than expected sales performance in the quarter, we were pleased to see evidence that our recently secured 510 clearances and our next generation generator system are resonating with the surgeon community."
Charlie Goodwin, President & CEO
"We are pleased with the strong operating leverage we demonstrated in the third quarter despite the softer than expected revenue results."
Tara Sem, Chief Financial Officer
Strategic Positioning
1. Capital Equipment Demand Reset
Persistent macro uncertainty and high interest rates have led surgeons to delay capital equipment purchases, particularly in the U.S. cosmetic surgery market. APYX responded by introducing new financing options and expects no near-term improvement in capital purchasing sentiment, shaping a more conservative outlook for Q4 and 2024.
2. Utilization and Consumable Revenue Focus
Handpiece sales, a recurring consumable revenue stream, now drive over half of Advanced Energy segment sales, highlighting the company’s shift toward utilization as the core growth engine. Management is investing in clinical evidence, direct-to-consumer awareness, and surgeon education to drive higher procedure volumes and repeat usage.
3. Commercial Execution Overhaul
Sales and marketing execution fell short in Q3, prompting a reorganization to improve productivity and accountability. Leadership expects these changes to yield incremental gains in Q4 and more material improvements in 2024, with a focus on both new customer acquisition and deeper engagement with existing users.
4. Regulatory and Product Differentiation
Recent FDA 510(k) clearances for aesthetic body contouring post-liposuction position Renuvion as the only device with this indication, providing a competitive edge. New product launches, including the APEX One console and Renuvion Micro Handpiece, are receiving positive feedback and are expected to contribute to growth as training and protocols scale up.
5. Financial Flexibility and CFO Transition
A new $45 million credit facility and improved cash position enhance APYX’s ability to invest in growth initiatives, but the announced CFO departure introduces transition risk. The company expects a smooth handoff but will need to maintain discipline through the leadership change.
Key Considerations
This quarter marks a strategic inflection for APYX as macro and operational headwinds force a recalibration of growth assumptions and execution priorities. The balance between capital sales and recurring revenue, as well as the effectiveness of the reorganized commercial team, will define the company’s trajectory into 2024.
Key Considerations:
- Capital Demand Volatility: Cosmetic surgery equipment purchases remain highly sensitive to macro trends and surgeon sentiment.
- Utilization-Driven Growth: Continued handpiece adoption and procedure volume recovery are essential to offset lumpy capital sales.
- Execution Risk: Recent sales and marketing reorg must translate into improved productivity and pipeline conversion.
- Regulatory Moat: Unique FDA clearances could drive competitive differentiation, but require ongoing education and awareness-building.
- Leadership Transition: CFO succession could disrupt momentum if not managed carefully, especially in a volatile market.
Risks
APYX faces outsized exposure to elective procedure demand, which is vulnerable to economic downturns and shifts in consumer confidence. The company’s reliance on capital equipment sales introduces volatility, while the salesforce reorganization and CFO transition add near-term execution risk. Competitive responses to new product launches and potential regulatory changes also warrant close monitoring.
Forward Outlook
For Q4, APYX guided to:
- Advanced Energy revenue growth of 26% to 35% year over year
- Sequential improvement in handpiece procedure volumes, but no improvement in capital equipment demand
For full-year 2023, management lowered guidance:
- Total revenue of $53 to $54 million (prior $59 to $62 million)
- Gross margin of approximately 66%
- Net loss of approximately $16 million, reflecting both operational and non-recurring costs
Management highlighted several factors that will shape performance:
- Sales and marketing reorganization impact on Q4 and 2024 productivity
- Continued macro and capital spending headwinds, with utilization as the main growth lever
Takeaways
APYX’s Q3 revealed both the resilience of its recurring consumable business and the vulnerability of its capital sales to macro shocks. The company’s response—focusing on utilization, reorganizing commercial teams, and leveraging regulatory wins—will be tested as it enters a period of leadership transition and persistent external headwinds.
- Handpiece Utilization Will Be the Key Performance Indicator: The shift from capital to consumable-driven revenue is now central to the growth story, with over half of segment revenue from handpieces.
- Commercial Execution Must Improve: The success of the sales and marketing overhaul will determine whether APYX can convert its product and regulatory advantages into sustained market share gains.
- Monitor Leadership and Macro Dynamics: The CFO transition and ongoing capital equipment demand softness add uncertainty, requiring close tracking of cash flow, margin, and pipeline trends in 2024.
Conclusion
APYX’s Q3 performance underscores the tension between robust product innovation and external headwinds in elective healthcare. While new regulatory clearances and product launches set the stage for growth, the company’s ability to drive utilization and navigate execution and leadership transitions will define its next chapter.
Industry Read-Through
APYX’s experience this quarter highlights a broader trend across medtech and elective procedure markets: capital equipment demand remains highly cyclical and sensitive to macro conditions, while recurring procedure-driven revenue offers more stability. Competitors in the aesthetic and surgical device space should note the growing importance of consumable utilization, regulatory differentiation, and commercial agility. The impact of GLP-1 weight loss drugs on skin laxity procedures also signals a potential new demand driver for minimally invasive technologies, benefitting companies with strong clinical positioning and surgeon adoption programs.